N4 Pharma (LON:N4P) Stock Price Down 4.3% – Here’s What Happened

N4 Pharma Plc (LON:N4P) dropped 4.3% during mid-day trading on Tuesday . The company traded as low as GBX 0.55 ($0.01) and last traded at GBX 0.55 ($0.01). Approximately 226,721 shares changed hands during trading, a decline of 93% from the average daily volume of 3,195,231 shares. The stock had previously closed at GBX 0.58 ($0.01).

N4 Pharma Price Performance

The business’s fifty day moving average is GBX 0.62 and its 200-day moving average is GBX 0.61. The company has a debt-to-equity ratio of 1.62, a current ratio of 22.73 and a quick ratio of 7.28. The firm has a market cap of £2.37 million, a PE ratio of -55.00 and a beta of -0.37.

About N4 Pharma

N4 Pharma is a biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.

RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.

N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.

N4 Pharma’s lead programme, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.